Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Bisphosphonate Use & Fracture Risk in Women With BC

Menopause; ePub 2016 Jul 18; Drieling, LaCroix, et al

There was a higher risk of any clinical fracture among postmenopausal women with breast cancer with bisphosphonate use of 8 or more years compared with 2 to 3 years of use. This according to a study of 887 postmenopausal women enrolled in the Women’s Health Initiative from 1993 to 1998, diagnosed with breast cancer after enrollment, and reporting bisphosphonate use of 2 years or more on a medication inventory administered in 2008 and 2009. Women (median age 76 years) were followed from completion of the medication inventory until 2014. Researchers found:

• There were 142 clinical fractures.

• 8 or more years of bisphosphonate use was associated with higher risk of fracture compared with 2 to 3 years of use (HR, 1.67), in the multivariate-adjusted analysis for fracture risk factors.

• There was no significant association of 4 to 7 years of use with fracture.

Citation: Drieling RL, LaCroix AZ, Beresform SA, et al. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: Findings from the Women’s Health Initiative. [Published online ahead of print July 18, 2016]. Menopause. doi:10.1097/GME.0000000000000696.